Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myeloid Malignancies 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Hematologic Diseases 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cytarabine 167fludarabine phosphate 102Cyclophosphamide 97Azacitidine 92Whole-Body Irradiation 78fludarabine 77Mycophenolic Acid 71Busulfan 68Tacrolimus 59Peripheral Blood Stem Cell Transplantation 55Decitabine 55Granulocyte Colony-Stimulating Factor 49Filgrastim 44Daunorubicin 44Cyclosporine 42Methotrexate 41Melphalan 41Etoposide 41Clofarabine 41Idarubicin 39Mitoxantrone 34Antilymphocyte Serum 34venetoclax 32thymoglobulin 23Thiotepa 23Stem Cell Transplantation 21Injections 16Gemtuzumab 16CPX-351 16Sirolimus 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid, Acute × cc-486 × Clear all
NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Bristol-Myers Squibb

Phase 2 Active not recruiting
19 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

Celgene

Phase 3 Completed
472 enrolled 24 charts 1 FDA
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01835587 2018-11-20

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Celgene

Phase 1/2 Completed
31 enrolled 30 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡